Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides ( > 500 mg/dL) Results Support

Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients Breadth of scientific evidence presented provides further insight into the unique ,

VASCEPA ® , compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CABG by 2 4% and 3 6 %, respectively, and key secondary composite first hard MACE, comprised of

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in